3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
12
Carcinoma, Non-Small-Cell Lung
12
Neoplasm Metastasis
11
Colorectal Neoplasms
9
Triple Negative Breast Neoplasms
8
Neoplasms
6
Lymphoma
6
Squamous Cell Carcinoma of Head and Neck
5
Carcinoma, Renal Cell
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Glioblastoma
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Liver Neoplasms
2
Hematologic Diseases
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Interventions
Amifostine
4
Filgrastim
3
Cyclophosphamide
3
Melphalan
2
Irinotecan
2
Cytarabine
2
Carboplatin
2
spartalizumab
1
sodium thiosulfate
1
sargramostim
1
lometrexol
1
etoposide phosphate
1
Vincristine
1
Temozolomide
1
Sirolimus
1
Procarbazine
1
Phenobarbital
1
Peripheral Blood Stem Cell Transplantation
1
Paclitaxel
1
Mannitol
1
Lomustine
1
Interleukin-2
1
Idarubicin
1
Genetic Therapy
1
Gemcitabine
1
Folic Acid
1
Fibroblast Growth Factor 7
1
Fecal Microbiota Transplantation
1
Drug Therapy
1
Deoxycytidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Drug-Related Side Effects and Adverse Reactions
×
spartalizumab
×
Clear all
NCT06302062
2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
Recruiting
23 enrolled